Results 11 to 20 of about 29,486 (214)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents [PDF]

Human Vaccines & Immunotherapeutics
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12–17 years), with and without pre-booster SARS-CoV-2 infection.
Amparo L. Figueroa, Kashif Ali, Gary Berman, Wenqin Xu, Weiping Deng, Bethany Girard, Anne Yeakey, Karen Slobod, Jacqueline Miller, Rituparna Das, Frances Priddy   +10 more
doaj   +2 more sources

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase [PDF]

New England Journal of Medicine, 2021
BACKGROUND At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19).
Hana M El Sahly, Susanne Doblecki-Lewis, Judith M Martin   +2 more
exaly   +2 more sources

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers [PDF]

BMC Infectious Diseases
Background Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited.
Suwarti Suwarti, Gilbert Lazarus, Sabighoh Zanjabila, Robert Sinto, Fransiska Fransiska, Theresia Deborah, Dwi Oktavia, Junaidah Junaidah, Santayana Santayana, Henry Surendra, Jeng Yuliana, Herlina Pardosi, Nunung Nuraeni, Saraswati Soebianto, Novi Dwi Susilowati, Decy Subekti, Ariel Pradipta, J. Kevin Baird, Le Van Tan, Susanna Dunachie, Anuraj H. Shankar, Erni J. Nelwan, Raph L. Hamers, SEACOVARIANTS Consortium   +23 more
doaj   +3 more sources

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge [PDF]

Immunity, 2021
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of SARS and MERS coronavirus vaccines. We used the SARS-CoV-2 MA10 mouse model of acute lung injury to evaluate the immune response and potential ...
Anthony T Dipiazza, Sarah R Leist, Olubukola M Abiona   +2 more
exaly   +3 more sources

Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trialResearch in context [PDF]

EClinicalMedicine
Summary: Background: Longitudinal changes in vaccination-induced immune response remain inadequately characterized in adolescents. We present long-term safety, immunogenicity, and COVID-19 incidence following a 2-dose mRNA-1273 100-μg primary series ...
Amparo L. Figueroa, Kashif Ali, Gary Berman, Honghong Zhou, Weiping Deng, Wenqin Xu, Stephanie Lussier, Bethany Girard, Frank J. Dutko, Karen Slobod, Anne Yeakey, Frances Priddy, Jacqueline M. Miller, Rituparna Das   +13 more
doaj   +2 more sources

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age [PDF]

Vaccines
Background/Objectives: Streptococcus pneumoniae with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults.
Tosin Omole, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias, Zelalem Endale, Gretchen Tamms, Tina M. Sterling, Lori Good, Tulin Shekar, Morgan Johnson, Natalie Banniettis, Ulrike K. Buchwald, Alejandra Esteves-Jaramillo   +12 more
doaj   +2 more sources

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases [PDF]

Nature Communications
Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across ...
Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Dean Follmann, Gregory Hachigian, Cynthia Strout, J. Scott Overcash, Susanne Doblecki-Lewis, Jennifer A. Whitaker, Evan J. Anderson, Kathleen Neuzil, Lawrence Corey, Frances Priddy, Joanne E. Tomassini, Mollie Brown, Bethany Girard, Dina Stolman, Veronica Urdaneta, Xiaowei Wang, Weiping Deng, Honghong Zhou, Avika Dixit, Rituparna Das, Jacqueline M. Miller, the COVE Trial Consortium   +24 more
doaj   +2 more sources

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE [PDF]

Infectious Diseases and Therapy
Introduction Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Sushma Kavikondala, Katrin Haeussler, Xuan Wang, Anne Spellman, Mary T. Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, Anna Krivelyova, Sonam Vats, Maria Nassim, Nitendra Kumar, Nicolas Van de Velde   +11 more
doaj   +2 more sources

Safety and Immunogenicity of the mRNA-1273 Coronavirus Disease 2019 Vaccine in Solid Organ Transplant Recipients. [PDF]

J Infect Dis
Figueroa AL, Azzi JR, Eghtesad B, Priddy F, Stolman D, Siangphoe U, Leony Lasso I, de Windt E, Girard B, Zhou H, Miller JM, Das R.   +11 more
europepmc   +3 more sources

Determinants of protective humoral response to mRNA-1273 and BNT162b2 vaccines in peritoneal dialysis patients: a prospective cohort study. [PDF]

BMC Nephrol
Dimitrov Y, Krummel T, Chantrel F, Heibel F, Kribs M, Hannedouche T.   +5 more
europepmc   +3 more sources